Unlock stock picks and a broker-level newsfeed that powers Wall Street.

XETRA - Delayed Quote EUR

Illumina, Inc. (ILU.DE)

68.12
+1.19
+(1.78%)
At close: April 24 at 5:35:47 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Jacob Thaysen Ph.D. CEO & Director 2.2M -- 1975
Mr. Kevin Carl Pegels Chief of Global Operations 813.19k -- 1968
Dr. Steven Barnard Ph.D. Chief Technology Officer 860.76k -- 1961
Stephanie Campos President -- -- --
Mr. Scott Ericksen VP & Chief Accounting Officer -- -- 1973
Mr. Brian Blanchett VP of Finance & Treasurer and Interim Head of Investor Relations -- -- --
Mr. Scott Davies Chief Legal Officer -- -- 1970
Mr. Jakob Wedel Chief Strategy & Corporate Development Officer -- -- 1972
Ms. Patricia Leckman Senior VP & Chief People Officer -- -- 1964
Mr. Todd P. Christian Head of Services, Arrays & Genomics Access -- -- --

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500 https://www.illumina.com
Sector: 
Healthcare
Full Time Employees: 
8,970

Description

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 3. The pillar scores are Audit: 8; Board: 1; Shareholder Rights: 2; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 8, 2025 at 8:00 PM UTC

Illumina, Inc. Earnings Date

Recent Events

Related Tickers